Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement

INDIANAPOLIS and SUZHOU, China , Aug. 18, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Innovent Biologics, Inc. (HKEX: 01801) today announced a global expansion of their strategic alliance for TYVYT ® (sintilimab injection), an anti-PD-1 monoclonal antibody immuno-oncology medicine